A growing body of clinical research attesting to cannabis’s success in treating autism continues to expand. In one of the latest studies, published in the most recent issue of the journal Frontiers in Neurology, patients with autism receiving “CBD-enriched” cannabis oil showed vast improvements in social interaction and communication, as well as other neurological benefits.
In this most recent study, researchers in Brazil monitored the progress of 18 patients with autism over a period of up to nine months. Each of the patients received a CBD-rich cannabis sativa extract with a CBD to THC ratio of 75 to 1. The patients received 4.6 milligrams of CBD per kilogram of body weight to 0.06 milligrams of THC—a not insignificant dose for someone weighing more than 100 pounds.
Three patients discontinued the treatment because of “adverse effects” during the first month, but of the 15 who continued, 14 showed “some level of improvement” in multiple categories of symptoms.
Nine of the patients—the ones who did not also have epilepsy as well as autism—showed “improvement equal to or above 30%” in at least one of the categories monitored, and four patients showed significant improvement in at least four categories, including social interaction and function, as well as the ability to sleep and stay focused.
It’s hard to say with certainty whether the CBD was doing the work or was merely one tool in a box doing its share of the work. But as the researchers noted, 10 of the 15 patients were on other medications prior to starting the study—and nine of the 10 still showed improvement after cutting out or reducing their other, non-cannabis medications.
“The results reported here are very promising,” the researchers wrote, “and indicate that CBD-enriched [cannabis] may ameliorate multiple [autism spectrum disorder] symptoms even in non-epileptic patients, with substantial increase in life quality for both … patients and caretakers.”